Clinical trial · Observational
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
Efficacy and Safety of Immune Checkpoint Inhibitors (ICIs) and Tyrosine Kinase Inhibitors (TKIs) Therapy for Hepatocellular Carcinoma (HCC)：a Multicenter, Retrospective Study on the Real-world in China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting the data of HCC treatment with system treatment (ICIs and TKIs) plus or without local treatment in the last 3 years, comprehensive assessment of their efficacy and safety, explore whether the efficacy of system treatment combination local treatment showed better effect compared with system or local monotherapy. Our study will find a new way to improve the prognosis of HCC patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Effects of Immunotherapy | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Programmed Cell Death 1 | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lenvatinib Oral Product | Drug | — | UNRESOLVED |
| Local treatment | Procedure | — | UNRESOLVED |
| PD-1 inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Systemic therapy
- description
- ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib)
- interventionNames
- Drug: Lenvatinib Oral Product
- Drug: PD-1 inhibitor
- label
- Local treatment
- description
- local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
- interventionNames
- Procedure: Local treatment
- label
- Triple therapy
- description
- Systemic therapy plus Local treatment: ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib) plus local treatment (TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc)
- interventionNames
- Drug: Lenvatinib Oral Product
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of hepatocellular carcinoma * Treated with ICIs (PD-1 or PDL-1) therapy plus TKIs (Lenvatinib or sorafenib) * Treated with local therapy (TACE, HAIC, RF ablation, microwave ablation, radiotherapy, etc) * Treated Treated with ICIs plus TKIs and local therapy * Have complete medical record that can complete the OR or 1 year OS assessment and follow-up. Exclusion Criteria: * Patients who do not have complete medical record and follow-up information after treatment； * The researchers have evidence that it is not suitable for this study
References
Publications (0)
Data not yet available